Myocardium at risk in patients with acute myocardial infarction can be assessed by use of the perfusion agent technetium Tc99m sestamibi. Studies with this agent have demonstrated significant myocardial salvage in patients treated with thrombolysis. Sequential imaging with technetium 99m sestamibi appears to offer advantages over other methods of assessing treatment benefit.
|Original language||English (US)|
|State||Published - Jan 1 1992|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine